New hope for hospital patients battling heart and kidney failure
NCT ID NCT07273838
Summary
This study is testing if adding a medication called dapagliflozin to standard hospital care helps patients who are hospitalized with both worsening heart failure and sudden kidney injury. Researchers will give 130 participants either the drug or a placebo for up to 14 days to see if it improves recovery, reduces symptoms, and is safe. The goal is to see if this drug can help patients get better faster and avoid complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
-
Yale New Haven Hospital-St. Raphael Campus
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Conditions
Explore the condition pages connected to this study.